About capivasert ib
AKT inhibitor anticancer medicine
Used for
- Treats certain advanced breast cancers with specific PIK3CA, AKT1, or PTEN changes, with fulvestrant.
Usual adult dose
400 mg by mouth twice daily for four days, followed by three days off, repeated weekly.
Common side effects
- Diarrhea
- Skin rash
- High blood sugar
- Nausea and vomiting
Important warnings
- Can cause severe diarrhea, skin reactions, and high blood sugar.
- Blood sugar should be checked before and during treatment.
- May harm an unborn baby; effective contraception is required during treatment and afterward.
- Treatment is prescribed and monitored by a cancer specialist.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for one month after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one month after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can raise capivasertib levels.
- Strong or moderate CYP3A inducers can lower capivasertib levels.
- Avoid grapefruit products, which may affect drug levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.